Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program

Tarih
2013
Yazar
Kim, Dennis
Gruenwald, Viktor
Ou, Yen-chuan
Panneerselvam, Ashok
Anak, Oezlem
van den Eertwegh, Alfonsus J. M.
Karakiewicz, Pierre
Bavbek, Sevil
Rha, Sun Young
Bracarda, Sergio
Bahl, Amit
Üst veri
Tüm öğe kaydını göster
Özet
OBJECTIVE To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program.
Bağlantı
http://hdl.handle.net/20.500.12627/43271
https://doi.org/10.1016/j.urology.2012.09.019
Koleksiyonlar